Recovery of smell sense loss by mepolizumab in a patient allergic to Dermatophagoides and affected by chronic rhinosinusitis with nasal polyps.

Q2 Medicine
Clinical and Molecular Allergy Pub Date : 2019-02-13 eCollection Date: 2019-01-01 DOI:10.1186/s12948-019-0106-2
Carlo Cavaliere, Cristoforo Incorvaia, Franco Frati, Daniela Messineo, Mario Ciotti, Antonio Greco, Marco de Vincentiis, Simonetta Masieri
{"title":"Recovery of smell sense loss by mepolizumab in a patient allergic to Dermatophagoides and affected by chronic rhinosinusitis with nasal polyps.","authors":"Carlo Cavaliere,&nbsp;Cristoforo Incorvaia,&nbsp;Franco Frati,&nbsp;Daniela Messineo,&nbsp;Mario Ciotti,&nbsp;Antonio Greco,&nbsp;Marco de Vincentiis,&nbsp;Simonetta Masieri","doi":"10.1186/s12948-019-0106-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chronic rhinosinusitis with nasal polyps (CRSwNP) frequently presents with dysfunction or loss of the sense of smell, resulting in a significant impairment in quality of life. The medical treatments currently available may improve the olfactory function in patients with CRSwNP, but such an outcome is generally only transitory. We report the case of a patient with CRSwNP who completely recovered from smell sense loss by treatment with mepolizumab.</p><p><strong>Case presentation: </strong>The patient was a 62-year-old female who has severe asthma induced by allergy to Dermatophagoides and concomitant CRSwNP. Any treatment for the latter, including oral and injective corticosteroids, was unsuccessful in the loss of smell. Due to the satisfaction of admission criteria to mepolizumab treatment for severe asthma, treatment was initiated on March 2018, resulting in good clinical control of both asthma and CRSwNP, and particularly in complete recovery of the smell loss after 4 months of treatment and still persisting.</p><p><strong>Conclusion: </strong>In this case report, the treatment with mepolizumab in a patient allergic to Dermatophagoides and affected by CRSwNP was associated with an improvement of anosmia. That finding may be explained by a reduction of the nasal obstruction by nasal polyps.</p>","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":"17 ","pages":"3"},"PeriodicalIF":0.0000,"publicationDate":"2019-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12948-019-0106-2","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Molecular Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12948-019-0106-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 10

Abstract

Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) frequently presents with dysfunction or loss of the sense of smell, resulting in a significant impairment in quality of life. The medical treatments currently available may improve the olfactory function in patients with CRSwNP, but such an outcome is generally only transitory. We report the case of a patient with CRSwNP who completely recovered from smell sense loss by treatment with mepolizumab.

Case presentation: The patient was a 62-year-old female who has severe asthma induced by allergy to Dermatophagoides and concomitant CRSwNP. Any treatment for the latter, including oral and injective corticosteroids, was unsuccessful in the loss of smell. Due to the satisfaction of admission criteria to mepolizumab treatment for severe asthma, treatment was initiated on March 2018, resulting in good clinical control of both asthma and CRSwNP, and particularly in complete recovery of the smell loss after 4 months of treatment and still persisting.

Conclusion: In this case report, the treatment with mepolizumab in a patient allergic to Dermatophagoides and affected by CRSwNP was associated with an improvement of anosmia. That finding may be explained by a reduction of the nasal obstruction by nasal polyps.

Abstract Image

Abstract Image

美波珠单抗治疗嗜皮草过敏并伴有鼻息肉的慢性鼻窦炎患者嗅觉丧失的恢复
背景:慢性鼻窦炎伴鼻息肉(CRSwNP)常表现为嗅觉功能障碍或丧失,导致生活质量显著下降。目前可用的医学治疗可能会改善CRSwNP患者的嗅觉功能,但这种结果通常只是暂时的。我们报告一例CRSwNP患者通过mepolizumab治疗从嗅觉丧失中完全恢复。病例介绍:患者为62岁女性,因对类皮草过敏及伴随的CRSwNP引起严重哮喘。对后者的任何治疗,包括口服和注射皮质类固醇,对嗅觉丧失都是不成功的。由于mepolizumab治疗重症哮喘符合入院标准,于2018年3月开始治疗,哮喘和CRSwNP均得到良好的临床控制,特别是治疗4个月后嗅觉丧失完全恢复并仍在持续。结论:在本病例报告中,mepolizumab治疗对皮肤病过敏并受CRSwNP影响的患者与嗅觉改善相关。这一发现可以用鼻息肉引起的鼻塞减少来解释。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical and Molecular Allergy
Clinical and Molecular Allergy Medicine-Immunology and Allergy
CiteScore
8.20
自引率
0.00%
发文量
11
审稿时长
13 weeks
期刊介绍: Clinical and Molecular Allergy is an open access, peer-reviewed, online journal that publishes research on human allergic and immunodeficient disease (immune deficiency not related to HIV infection/AIDS). The scope of the journal encompasses all aspects of the clinical, genetic, molecular and inflammatory aspects of allergic-respiratory (Type 1 hypersensitivity) and non-AIDS immunodeficiency disorders. However, studies of allergic/hypersensitive aspects of HIV infection/AIDS or drug desensitization protocols in AIDS are acceptable. At the basic science level, this includes original work and reviews on the genetic and molecular mechanisms underlying the inflammatory response.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信